Jennifer Kherani

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson et al. · New England Journal of Medicine · 2020 · 731 citations · Full text

Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard et al. · Clinical Cancer Research · 2021 · 133 citations · Full text

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Ezra Y. Rosen, Melissa L. Johnson, Sarah Clifford et al. · Clinical Cancer Research · 2020 · 121 citations · Full text

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Ezra Y. Rosen, Helen Won, Youyun Zheng et al. · Nature Communications · 2022 · 104 citations · Full text

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

Alexander Drilon, Geoffrey R. Oxnard, Lori J. Wirth et al. · Journal of Thoracic Oncology · 2019 · 80 citations · Full text

Phase 1/2, Pl02.08 Registrational Results, Medicine +8